Bayer Patent-Cliff Exposure & CMS Drug Spending Portfolio
Bayer (Whippany, NJ): 39 reconciled FDA prescription therapies (6.2% 2025 to 2030 cliff risk), $2.92B 2024 CMS Part D & Medicaid spend, and 42 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | Whippany, NJ |
| Reconciled FDA Portfolio Therapies | 39 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 6.2% |
| Primary Portfolio LOE Date | 2027-01-01 |
| 2024 CMS Total Public Spend | $2.92B |
| 2024 Medicare Part D Spend | $2.33B |
| 2024 Medicaid Spend | $592.3M |
| California HCAI SB 17 Filings | 42 WAC filings (max 22.9% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Bayer across sibling Meru public-data platforms.
- Predicate Ledger FDA 510(k)Bayer FDA 510(k) & Recall Cohortdevices.meruai.co →
- Protocol Ledger NIH ClinicalTrials.govBayer Clinical Trials & Approvalstrials.meruai.co →
- ERISA Ledger DOL Form 5500Bayer 401(k) & Form 5500 Planerisa.meruai.co →
- Plume Ledger EPA TRI & RCRABayer U.S. TRI & RCRA Facilitieshazmat.meruai.co →